DOCSLIB.ORG

National List of Essential Medicines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National List of Essential Medicines ( 1 ) ( 2 ) Classifications Route of administration, Classifications Route of administration, Generic Name (INN) dosage forms and strengths Generic Name (INN) dosage forms and strengths SECTION 1: ANAESTHETICS Infiltration 5-10mg/ml ,0.5 to 1% 1.1 General Anaesthetics Regional 5mg/ml, 0.5 % 1.1.1Inhalational Anaesthetics and Oxygen - Ephedrine (E) Injection 30mg/ml Volatile Liquid Anaesthetics (hydrochloride) - Isoflurane (E) 1.3. Pre-operative medication and sedation - Diethyl Ether (E) - Atropine (E) Injection 600mcg/ml (sulfate) - Halothane (E) Gaseous Anaesthetics - Glycopyronium (E) Injection 600mg/3ml ampoule (bromide) - Nitrous oxide (E) - Promethazine (E) Oral Liquid 5mg/5ml Oxygen (E) (Hydrochloride) 1.1.2 Intravenous Anaesthetics SECTION 2: ANALGESICS , ANTIPYRETICS,NON-STEROIDAL ANTI- - Propofol (E) Injection 10mg/ml, 1% INFLAMMATORY MEDICINES (NSAIMs) , MEDCINES - Ketamine (E) Injection 10mg/ml, 50mg/ml USED TO TREAT GOUT AND DISEASE MODIFYING (hydrochloride) AGENTS IN RHEUMATOID DISORDERS (DMARDs) - Thiopental (C) Injection 25mg/ml, 2.5% 2.1 Non-opioids - Aspirin(E) Tablet 300mg 1.2 Local Anaesthetics (sulfate) (soluble/ dispersable forms) - Bupivacaine (E) Spinal 0.5% heavy 5mg/ml - Diclofenac (E) Tablet 25mg,50mg (hydrochloride) +7.5% glucose (sodium/potassium) Injection 25mg/ml in 3ml ampoule Nerve block 2.5-5mg/ml, 0.25-0.5% Suppository 12.5mg, 25mg, Epidural block 2.5-5mg/ml, 0.25-0.5% 50mg,100mg - Lignocaine (E) Spinal 5% heavy 50mg/ml - Paracetamol (E) Tablet 500mg + 7.5% glucose Suppository 80mg,125mg,150mg, (hydrochloride) Nerve block 15-20mg/ml,1.5 to 2% 300mg, 600mg Epidural block 15-20mg/ml,1.5 to 2% Oral Liquid 120mg/5ml Lozenge 5% - Celecoxib (C)* Tablet 100mg, 200mg Dental Cartridge 2%+1:80,000 adrenaline (Selective COX 2 inhibitor) Spray 10% ( 3 ) ( 4 ) Classifications Route of administration, Classifications Route of administration, Generic Name (INN) dosage forms and strengths Generic Name (INN) dosage forms and strengths 2.2. Opioid Analgesics - Dexamethasone (E) Tablet 500mcg (sodium phosphate) Injection 4mg/ml in 1ml, 2ml amp. - Codeine (E) Tablet 30mg (phosphate) - Hydrocortisone (E) Cream/Ointment 0.5%, 1% (acetate) - Morphine (E) Injection 10mg, 15mg/ml (sodium succinate/ Injection 100mg, 500mg vial (sulfate/hydrochloride) Tablet/Oral Liquid 50mg sodium phosphate) - Pethidine (E) Injection 50mg, 100mg/ml - Prednisolone (E) Tablet 5mg (hydrochloride) Tablet 50mg - Cetirizine (E) Tablet 10mg - Fentanyl (E) (citrate) Injection 50mcg/ml ,2 ml amp (hydrochloride) Syrup 5mg/5 ml - Tramadol (E) Capsule/Tablet 50mg, 100mg - Fexophenadine (C) Tablet 30mg, 60mg (Hydrochloride) Injection 50mg/ml, 2ml SECTION 4: ANTIDOTES AND OTHER SUBSTANCES USED 2.3 Medicines used to treat gout & hyperuraecemic condition IN POISONING - Allopurinol (E) Tablet 100mg 4.1 Nonspecific - Colchicine (E) Tablet 500mcg - Activated Charcoal (E) Powder/granules25g, 50g sachet Suspension 50g pack - Probenecid (C) Tablet 500mg 4.2 Specific 2.4 Disease Modifying Agents in Rheumatoid Disorders - Acetylcysteine (E) Injection 200mg/ml in 10 ml - Leflunomide (E) Tablet 10mg, 30mg ampoule - Sulfasalazine (C) Tablet 500mg - Deferoxamine (E) Powder for 500mg in vial (Mesilate) Injection SECTION 3 : ANTI - ALLERGICS AND MEDICINES USED IN - Dimercaprol (E) Injection 50mg/ml in 2ml ampoule ANAPHYLAXIS - Naloxone (E) Injection 400mcg in 1ml ampoule - Epinephrine (E) Injection 1:1000, 1:10000 (hydrochloride) (hydrogen tartrate) (1mg/ml,0.1 mg/ml amp) - Penicillamine (E) Capsule/Tablet 250mg - Chlorphenamine (E) Tablet 4mg - Pralidoxime (E) Injection 200mg/ml in 5ml amp (mesilate) (maleate) Injection 10mg/ml ( 5 ) ( 6 ) Classifications Route of administration, Classifications Route of administration, Generic Name (INN) dosage forms and strengths Generic Name (INN) dosage forms and strengths - Flumazenil (E) Injection 100mcg/ ml in 5ml amp SECTION 6: ANTI-INFECTIVE MEDICINES - Sodium Nitrite (C) Injection 30mg/ml in 10ml amp 6.1 Anthelmintics - Sodium Thiosulphate (C) Injection 250mg/ml in 50ml amp 6.1.1 Intestinal Anthelmintics SECTION 5: DRUGS FOR CENTRAL NERVOUS SYSTEM - Niclosamide (C) Tablet 500mg 5.1 Anticonvulsants, Antiepiletics - Albendazole (E) Tablet 400mg - Carbamazepine(E) Tablet 100mg, 200mg - Levamisole (E) Tablet 25mg - Diazepam (E) Injection, 5mg/ml in 2ml amp Rectal solution 2.5mg, 5mg, 10mg 6.1.2 Antifilarials 20mg in rectal tube - Diethylcarbamazine (E) Tablet 50mg - Midazolam (E) Injection 10mg/2ml (citrate) - Ethosuximide (C) Capsule 250mg 6.2 Antibacterials Syrup 250mg/5ml 6.2.1 Penicillins - Magnesium sulfate (E) Injection 500mg in 2ml (25%) 4g in 20ml (20%) - Amoxicillin (E) Capsule/Tablet 250mg, 500mg (trihydrate) Dry Syrup 125mg/5ml - Phenobarbital (E) Tablet 15mg, 30mg, 60mg (sodium salt) Injection 500mg, 1g vial (sodium salt) Oral Liquid 15mg/ml Injection 20mg/ml amp - Amoxicillin with clavulinic Tablet 375mg, 625mg acid (Co-amoxiclav) (E) Suspension 156mg - Sodium Valporate (E) Tablet 200mg, 500mg (125mg+31mg), Suspension 312mg/ 5 ml(250+62mg) 5.2 Drugs for Parkinsonism Injection 600mg(500mg+100mg), - Levodopa + Carbidopa(E) Tablet 100mg + 10 mg 1.2g(1000mg+200mg)/vial 250mg + 25 mg Oral Liquid 200mg/5ml - Benzathine penicillin (E) Injection (1.44 g benzyl penicillin) 1.2 million IU in 5 ml vial - Benzhexol (E) Tablet 2mg - Benzylpenicillin G (E) Injection 1 IU = 0.6mcg potency - Orphenadrine (C) Tablet 50mg (sodium / potassium salt) single or multiple dose vial (Hydrochloride) ( 7 ) ( 8 ) Classifications Route of administration, Classifications Route of administration, Generic Name (INN) dosage forms and strengths Generic Name (INN) dosage forms and strengths - Cephalexin (E) Tablet/Capsule 250mg, 500mg 6.2.2 Other Antibacterials Oral Liquid 125, 250mg/5ml - Chloramphenicol (E) - Cefuroxime (C)* Tablet(as axetil) 125mg, 250mg (palmitate) Oral Liquid 150mg/5ml (sodium salt) Oral Liquid 125mg/5ml (sodium succinate) Injection 500mg, 1g vial Injection 250mg, 750mg/vial Eye drop 0.5% Ointment 1% - Cefaclor (C)* Capsule 250mg, 500mg Oral Liquid 125mg, 250mg/5ml - Co-trimoxazole (E) Tablet 120mg, 480mg (Sulfamethoxazole Oral Liquid 240mg/5ml + Trimethoprim - 5:1) Injection 96mg/ml in 5ml,10ml amp - Ceftriaxone (C) * Injection 1g, 2g/vial - Doxycycline (E) Capsule/Tablet 100mg (sodium salt) (hyclate) - Cefipirome (C) Injection 1g, 2g/vial - Tetracycline Eye ointment 1% - Cefixime (C) Capsule/Tablet 100mg, 200mg - Erythromycin (E) Capsule/Tablet 250mg - Ceftazidime (C)* Injection 1g, 2g/vial (stearate/ethylsuccinate) Oral Liquid 125mg, 250mg/5ml (pentahydrate) (lactobionate) Injection 500mg, 1g vial - Flucloxacillin (E) Capsule 250mg, 500mg - Azithromycin (E) Tablet/Capsule 250mg, 500mg (sodium) Oral Liquid 125mg/ 5ml (dihydrate) Oral Liquid 200mg/ 5ml Injection 500mg, 1g vial - Gentamicin (E) Injection 10mg, 40mg/ml - Phenoxymethyl- Tablet 250mg (sulfate) in 2ml ampoule penicillin (E) Oral Liquid 250mg/ 5ml Eye drop 0.3% (potassuim salt) - Amikacin (C)* Injection 500mg in 2ml vial - Fortified Procaine Injection mixture of 5 parts of (sulfate) Penicillin G (E) procaine penicillin and 1 - Netilmicin (C)* Injection 50mg, 100mg/ml amp part of benzylpenicillin (sulfate) single or multiple dose vial - Metronidazole (E) Tablet 200mg - Imipenam + cilastatin (C) Injection 500mg+ 500mg (benzoate) Injection 500mg/100ml vial (monohydrate) Oral Liquid 200mg/5ml - Piperacillin + tazobactam (C) Injection 2g + 250mg - Neomycin (C) Tablet 500mg (sulfate) Oral Liquid 100mg/5ml ( 9 ) ( 10 ) Classifications Route of administration, Classifications Route of administration, Generic Name (INN) dosage forms and strengths Generic Name (INN) dosage forms and strengths - Norfloxacin (E) Tablet 400mg Drop (Ear/Nose) 0.3% - Streptomycin (E) Injection 1g/ vial (sulfate) - Ciprofloxacin (E) Tablet 250mg, 500mg Oral Liquid 250mg/ 5ml Second - line medicines for the tratement of multidrug-resistant Injection 200mg/ 100ml vial tuberculosis (MDR-TB) Eye/Ear Drop 0.3% - Aminosalicylic acid(C) Granules 4g /sachet - Clindamycin (C) Capsule 150mg, 300mg Tablet 500 mg Injection 300mg/ 2ml - Capreomycin(C) Injection 1000mg in vial - Vancomycin (C) Injection 500mg vial Tablet 125mg, 250mg - Cycloserine(C) Capsule/Tablet 250mg - Lincomycin (C) Injection 500mg - Ethionamide (C) Tablet 125mg, 250mg Capsule 250mg, 500mg - Kanamycin(C) Injection 1000mg in vial - Sulphadiazine (C) Injection 1g in 4 ml amp - Ofloxacin(C) Tablet 200mg, 400mg Tablet 500mg 6.2.3. Antileprotic Medicines 6.3. Antifungal Medicines - Clofazimine (E) Capsule 50mg, 100mg - Amphotericin B (C)* Injection 50mg, 100mg vial (salt complex or - Dapsone (E) Tablet 150mg, 300mg lipid complex forms) 6.2.4. Antituberculous Medicines - Ketoconazole (E) Tablet 200mg Oral Liquid 100mg/ 5ml - Ethambutol (E) Tablet 400mg Cream 2% (hydrochloride) (E) - Fluconazole (E) Capsule 50mg, 150mg, - Isonizaid (E) Tablet 100mg, 300mg 200mg - Nystatin (E) Oral Liquid 100,000 units/g - Pyrazinamide (E) Tablet 500mg Lozenge 100,000 IU - Rifampicin (E) Capsule/Tablet 150mg, 300mg, Tablet 100,000 IU, 450mg 500,000 IU Chewable Tablet 100mg Pessary 100,000 IU Oral Liquid 100mg/5ml ( 11 ) ( 12 ) Classifications Route of administration, Classifications Route of administration, Generic Name (INN) dosage forms and strengths Generic Name (INN) dosage forms and strengths - Clotrimazole (E) Eye Drop 1% - Quinine (E) Tablet 300mg Drop (Ear/Nose) 1% (sulfate) Cream 1%, 10% (dihydrochloride) Injection 300mg/ml in 2ml amp Vaginal Tablet 100mg, 500mg - Amodiaquine (E) Tablet 150mg, 200mg 6.4. Anti-protozoal Medicines (as hydrochloride)
Load more

Recommended publications
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Local Anesthetics – Substances with Multiple Application in Medicine
    ISSN 2411-958X (Print) European Journal of January-April 2016 ISSN 2411-4138 (Online) Interdisciplinary Studies Volume 2, Issue 1 Local Anesthetics – Substances with Multiple Application in Medicine Rodica SÎRBU Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Emin CADAR UMF Carol Davila Bucharest, Faculty of Pharmacy, Str. Traian Vuia No. 6, Sector 2, Bucharest, Romania Cezar Laurențiu TOMESCU Ovidius University of Constanta, Faculty of Medicine, Campus Corp B, University Alley No. 1, Constanta, Romania Cristina-Luiza ERIMIA Corresponding author, [email protected] Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Stelian PARIS Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Aneta TOMESCU Ovidius University of Constanta, Faculty of Medicine, Campus Corp B, University Alley No. 1, Constanta, Romania Abstract Local anesthetics are substances which, by local action groups on the runners, cause loss of reversible a painful sensation, delimited corresponding to the application. They allow small surgery, short in duration and the endoscopic maneuvers. May be useful in soothe teething pain of short duration and in the locking of the nervous disorders in medical care. Local anesthesia is a process useful for the carrying out of surgery and of endoscopic maneuvers, to soothe teething pain in certain conditions, for depriving the temporary structures peripheral nervous control. Reversible locking of the transmission nociceptive, the set of the vegetative and with a local anesthetic at the level of the innervations peripheral nerve, roots and runners, a trunk nervous, around the components of a ganglion or coolant is cefalorahidian practice anesthesia loco-regional.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Contact Dermatitis to Medications and Skin Products
    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
    [Show full text]
  • University of Groningen Dermatological Preparations for The
    University of Groningen Dermatological preparations for the tropics. A formulary of dermatological preparations and background information on choices, production and dispensing. Bakker, Peter; Woerdenbag, Herman; Gooskens, Vincent; Naafs, Ben; Kaaij, Rachel van der; Wieringa, Nicolien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2012 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Bakker, P., Woerdenbag, H., Gooskens, V., Naafs, B., Kaaij, R. V. D., & Wieringa, N. (2012). Dermatological preparations for the tropics. A formulary of dermatological preparations and background information on choices, production and dispensing. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date:
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    358 1998/74 MEDICINES AMENDMENT REGULATIONS 1998 THOMAS EICHELBAUM, Administrator of the Government ORDER IN COUNCIL At Wellington this 20th day of April 1998 Present: THE HON JENNY SHIPLEY PRESIDING IN COUNCIL PURSUANT to section 105 of the Medicines Act 1981, His Excellency the Administrator of the Government, acting by and with the advice and consent of the Executive Council, and on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representative of persons likely to be substantially affected, makes the following regulations. ANALYSIS 1. Title and commencement SCHEDULE 2. New First Schedule substituted New First Schedule of Principal Regulations 3. Revocation 1998/74 Medicines Amendment Regulations 1998 359 REGULAnONS 1. Title and commencement-( 1) These regulations may be cited as the Medicines Amendment Regulations 1998, and are part of the Medicines Regulations 1984"- ("the principal regulations"). (2) These regulations come into force on 1 June 1998. 2. New First Schedule substituted-The principal regulations are amended by revoking the First Schedule, and substituting the First Schedule set out in the Schedule of these regulations. 3. Revocation-The Medicines Regulations 1984, Amendment No. 7 (S.R. 1996/367) are consequentially revoked. ·S.R. 1984/143 Amendment No.1: (Revoked by S.R. 1996/367) Amendment No.2: (Revoked by S.R. 1996/367) Amendment NO.3: S.R. 1990/221 Amendment No.4: S.R. 1991/134 Amendment NO.5: S.R. 1992/43 Amendment NO.6: S.R. 1994/299 Amendmem No.7: 5 R 1996/367 Amendment 1997: S.R.
    [Show full text]
  • Appendices: V Ervolgonderzoek Medicatieveiligheid
    APPENDICES: V ERVOLGONDERZOEK MEDICATIEVEILIGHEID Dit is een bijlage bij het rapport Vervolgonderzoek Medicatieveiligheid en is opgesteld voor het Ministerie van VWS vanuit een samenwerkingsverband tussen het Erasmus MC (Rotterdam), NIVEL (Utrecht), Radboud UMC (Nijmegen) en PHARMO (Utrecht) Januari 2017 Versie 1.0 1 Appendices Hoofstuk 2: Onderzoek naar de mate van opvolging van HARM-Wrestling aanbevelingen (2009-2014) 2 Appendix 1 Appendix 1: Technische omzetting van HARM-Wrestling aanbevelingen naar indicatoren Algemene specificaties Tabel A1a. Bepaling van medicatiegebruik. Geneesmiddel of ATC-code geneesmiddelen groep Antidepressiva N06A Laag gedoseerd ASA B01AC06, B01AC08, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Benzodiazepinen N05CF, N05CD, N05BA of N05CC Beta-blokkers C07 Bisfosfonaten M05BA, M05BB, of M05XX Calcineurine remmers L04AA05 of L04AD01 Carbamazepine N03AF01 Corticosteroiden H02AB Co-trimoxazol J01EE01 Coxibs M01AH Diabetesmedicatie A10 Digoxine C01AA05 Glibenclamide A10BB01 of A10BD02 of A10BD04 H2RA A02BA Itraconazol J02AC02 Kaliumsparende diuretica C03DA, C03DB, of C03EA Kaliumverliezende diuretica C03A, C03B, C03E, C07B, C07CB03, C09BA, C09DA, C09XA52, C03C of C09DX01 Ketoconazol J02AB02 Niet-selectieve NSAID’s N02BA01, N02BA15, N02BA11, N02BA51, N02BA65 of M01A met uitzondering van M01AH, M01AX05, M01AX12, M01AX21, M01AX24, M01AX25 en M01AX26 Laxantia A06A, A02AA02, A02AA03, A02AA04, A06AC, A06AA, of A06AG Lisdiuretica C03C Macroliden J01FA of A02BD04 VKA B01AA Opioïden N02AA met uitzondering van N02AA55, N02AA59 en N02AA79, N02AB, N02AC, N02AD, N02AG, N02AE of N07BC01 Pentamidine P01CX01 PPI’s A02BC of M01AE52 RAS-remmers C09 Sotalol C07AA07 Spironolacton C03DA01 SSRI's N06AB, N06AX21 of N06AX16 Sulonylureumderivaten A10BB, A10BD02 of A10BD04 Thiazidediuretica C03A, C03B, C03EA, C07B, C09BA, C09DA, C09XA52, C09DX01 of C07CB03 TAR B01AC04, B01AC06, B01AC08, B01AC22, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Thienopyridine derivaten B01AC04, B01AC22 of B01AC30 3 Appendix 1 Tabel A1b.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]